A Randomized Placebo-Controlled Study to Evaluate the Effects of a Gummy and Capsule Supplement on Symptoms of Premenstrual Syndrome
NCT ID: NCT06763809
Last Updated: 2025-01-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
176 participants
INTERVENTIONAL
2024-09-04
2024-12-12
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Single Group Study to Evaluate the Effects of a Supplement on Premenstrual Syndrome
NCT06124326
Study to Evaluate the Efficacy of Elix's Cycle Balance and Its Impact on PMS and Menstrual Symptoms
NCT05145257
A Clinical Study to Assess the Effect of a Dietary Supplement on Menstrual Cycle Symptoms
NCT07267728
Effects of a Female Hormone Balance Supplement on Premenstrual Syndrome Symptoms
NCT07018479
Comparison Between Oral Contraceptive Pills and Calcium Supplements in Treatment of Premenstrual Syndrome
NCT02089620
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PMS Capsule Group
Participants in this arm will take the PMS capsule, which contains Vitamin D3, Magnesium, Quercetin, Curcumin, Boswellia, Milk Thistle Extract, Resveratrol, and Ashwagandha.
PMS Capsule
Participants will take 2 capsules, 4 times daily, starting at the onset of PMS symptoms and continuing until symptoms subside.
Capsule Placebo Group
Participants in this arm will take a placebo capsule, containing microcrystalline cellulose and other inert ingredients.
Capsule Placebo
Participants will take 2 capsules, 4 times daily, starting at the onset of PMS symptoms and continuing until symptoms subside.
PMS Gummy Group
Participants in this arm will take the PMS gummy, which contains Vitamin D3, Magnesium, Quercetin, Curcumin, Lemon Balm Extract, Milk Thistle Extract, and Resveratrol.
PMS Gummy
Participants will take 2 gummies, 4 times daily, starting at the onset of PMS symptoms and continuing until symptoms subside.
Gummy Placebo Group
Participants in this arm will take a placebo gummy, containing inert ingredients such as tapioca syrup, cane sugar, and citric acid.
Gummy Placebo
Participants will take 2 gummies, 4 times daily, starting at the onset of PMS symptoms and continuing until symptoms subside.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PMS Capsule
Participants will take 2 capsules, 4 times daily, starting at the onset of PMS symptoms and continuing until symptoms subside.
Capsule Placebo
Participants will take 2 capsules, 4 times daily, starting at the onset of PMS symptoms and continuing until symptoms subside.
PMS Gummy
Participants will take 2 gummies, 4 times daily, starting at the onset of PMS symptoms and continuing until symptoms subside.
Gummy Placebo
Participants will take 2 gummies, 4 times daily, starting at the onset of PMS symptoms and continuing until symptoms subside.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Must be in good health with no significant chronic conditions (such as oncological or psychiatric disorders) and a BMI under 35.
* Must experience at least five of the following symptoms during their menstrual cycle:
Menstrual pain, Menstrual cramping, Increased Irritability, Mood changes, Breast tenderness, Headaches/migraines, Bloating, Fatigue, Constipation or diarrhea, Sleep disturbances
* Must have a regular menstrual cycle with a bleed week, and must be currently tracking their menstrual cycle and able to accurately predict their bleed week.
* If using hormonal contraception, must do so for at least three months before starting the trial, and remain consistent with taking it as per healthcare provider instructions during the study.
* If using hormonal contraception, must allow for a bleed week every month.
* Must agree to avoid cannabis, CBD, ashwagandha, and supplements other than multivitamins or protein powders for 24 hours prior to the study, and during the full study duration.
* Willing to refrain from OTC pain medications or supplements to target period-related symptoms during the study period.
* Must live in the United States.
Exclusion Criteria
* Anyone currently undergoing or planning to undergo during the study period, any gynecological-related procedures.
* Anyone diagnosed with Graves disease, Hashimotos or taking any medication for their thyroid.
* Anyone who has undergone any surgeries or invasive treatments in the last six months, or is planning to during the study period.
* Anyone with any allergic reactions requiring the use of an Epi-pen.
* Anyone with known severe allergic reactions, or history of allergy or intolerance to ingredients found in over-the-counter dietary, vitamin or herbal supplements.
* Anyone with any allergies or sensitivities to any of the study product ingredients.
* Anyone with known allergies to nightshades (e.g., eggplant, tomato, bell pepper, potato).
* Unwilling to follow the study protocol.
* Anyone pregnant, breastfeeding, or trying to conceive currently or for the duration of the study.
Participants will self-report that they are not pregnant.
* Current use of an extended activity hormonal contraception (examples include Depo-Provera injection, Nexplanon implant, or hormonal intrauterine devices (IUDs)).
* Currently participating in any other clinical study or planning to at any point during this study's duration.
* Anyone who has an alcohol dependency, regularly uses cannabis, or is using illicit drugs.
* Anyone with a history of substance abuse.
* Anyone who regularly takes supplements that might reduce inflammation or is planning to at any point during the study period.
* Anyone currently taking prescription pain medication for any indication.
* Anyone who is currently taking, or planning to take during the study period, any medications, supplements or products targeted at improving Premenstrual Syndrome symptoms.
18 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Citruslabs
INDUSTRY
Semaine Health
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Citruslabs
Las Vegas, Nevada, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
20670
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.